June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Posterior vitreous status did not impact ranibizumab treatment outcomes in HARBOR study patients with neovascular AMD
Author Affiliations & Notes
  • Michelle V Carle
    EyeQ Vision Care, Fresno, California, United States
  • Lauren Hill
    Genentech, South San Francisco, California, United States
  • Tatiana Ecoiffier
    Genentech, South San Francisco, California, United States
  • Shamika Gune
    Genentech, South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Michelle Carle, None; Lauren Hill, Genentech (E); Tatiana Ecoiffier, Genentech (E); Shamika Gune, Genentech (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 407. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Michelle V Carle, Lauren Hill, Tatiana Ecoiffier, Shamika Gune; Posterior vitreous status did not impact ranibizumab treatment outcomes in HARBOR study patients with neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2017;58(8):407.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The status of the posterior vitreous (PV) may play a role in inflammatory processes and oxygenation status of the retina. Whether the PV is attached or detached may impact the effect of anti-VEGF treatment of retinal diseases and the HARBOR study dataset may inform us of any correlation between PV status and ranibizumab treatment outcomes in the setting of Neovascular AMD. We evaluated the impact of posterior vitreous (PV) status on 24-month ranibizumab (RBZ)-treatment outcomes in HARBOR study patients with neovascular AMD using a retrospective data analysis of existing OCT scans.

Methods : A retrospective analysis of OCT scan data obtained on patients during treatment in the HARBOR study was performed to determine PV status based on macular cube scans from all scheduled visits. There was no variable that directly assessed posterior vitreous detachment (PVD); the posterior hyaloid attachment/detachment was used to determine PVD. Status was categorized as: PV detached/not detectable (PVD) or attached (no PVD). If a patient had PVD once, they were considered to have PVD at all remaining visits. If a patient did not have PVD at baseline, they could switch to PVD. PVD status between three groups (PVD at baseline and persistent throughout, PVD developed during treatment, and never developed PVD) were compared using BCVA changes from baseline as well as changes in central subfield thickness during the 24 month course of treatment with ranibizumab.

Results : There were no clinically meaningful differences between eyes with (840) or eyes without (249) PVD at baseline for mean (95% CI) changes from baseline to Month 24 in BCVA (letters; 8.3 [7.2, 9.4] vs 10.5 [8.4, 12.5], respectively) or central subfield thickness (CST, µm; -152 [-161, -143] vs -149 [-167, -131], respectively). For eyes without PVD at baseline, there were no clinically meaningful differences between eyes that did (193)/did not (56) develop PVD during the study for mean changes from baseline to Month 24 in BCVA (10.6 [8.2, 13.0] vs 10.0 [5.8, 14.3], respectively) or CST (-156 [-177, -134] vs -126 [-161, -90], respectively).

Conclusions : There was no relationship between PV status and BCVA or CST outcomes at Month 24 in the HARBOR study.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×